DexCom, Inc.
DXCM Healthcare Medical Devices
DexCom, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.7 billion, up 15.6% from fiscal 2024. In the quarter to June 2026, revenue grew 13.1%, EPS grew 41.3%, free cash flow fell 11.7% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; revenue growth for ten consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
Follow DXCM
DexCom, Inc. 10-Q filed Jul 30, 2026
What changed
Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Apr 30, 2026: 1 added · 12 modified; 8 with only figures updated
-
Modified · Critical Accounting Estimates
Overview of Financial Results The most important financial indicators that we use to assess our business are revenue, gross profit, operating income, net income, and operating cash flow. Key Highlights for the Three Months Ended
March 31June 30, 2026 include the following: Revenue | Gross Profit | Operating Income | Net Income | Operating Cash Flow $1.191.31 billion | $750.3830.0 million | $255.3318.3 million | $199.5249.1 million | $525.6269.2 million up1513% from the same period in 2025 | up2720% from the same period in 2025 | up9150% from the same period in 2025 | up8939% from the same period in 2025 |up 186down 11% from the same period in 2025
12 more changes in this Item, word by word, in Powerpack.
Powerpack